Matsuzaki T, Haruno A, Hashimoto K
Department of Pharmacology, Yamanashi Medical College, Japan.
Eur J Pharmacol. 1993 Feb 16;231(3):363-70. doi: 10.1016/0014-2999(93)90111-t.
The antiarrhythmic effects of gallopamil on adrenaline-, digitalis- and two-stage coronary ligation-induced arrhythmias and on adrenaline-induced triggered arrhythmia were investigated. Gallopamil suppressed adrenaline-induced and adrenaline-induced triggered arrhythmias, and these antiarrhythmic effects of gallopamil were similar to those of verapamil. Gallopamil also showed some antiarrhythmic effect on the 48-h coronary ligation-induced arrhythmia. The plasma concentration of gallopamil which decreased the arrhythmic ratio for adrenaline-induced arrhythmia by 50% (IC50) was 32 ng/ml. These results indicate that gallopamil may be a clinically useful antiarrhythmic drug.
研究了加洛帕米对肾上腺素、洋地黄和两阶段冠状动脉结扎诱发的心律失常以及对肾上腺素诱发的触发心律失常的抗心律失常作用。加洛帕米抑制肾上腺素诱发的和肾上腺素诱发的触发心律失常，且加洛帕米的这些抗心律失常作用与维拉帕米相似。加洛帕米对48小时冠状动脉结扎诱发的心律失常也显示出一定的抗心律失常作用。使肾上腺素诱发心律失常的心律失常发生率降低50%（半数抑制浓度）时的加洛帕米血浆浓度为32纳克/毫升。这些结果表明加洛帕米可能是一种临床上有用的抗心律失常药物。
